Literature DB >> 3904868

Abnormal clonogenic potential of T cells from multiple myeloma patients.

L M Pilarski, M J Mant, B A Ruether, G Carayanniotis, D Otto, J F Krowka.   

Abstract

Peripheral blood lymphocytes (PBLs) from multiple myeloma patients are defective in both proportion and absolute numbers of OKT4+ cells and have a normal proportion but reduced absolute number of OKT8+ cells. To assess the functional capabilities of the T cells in myeloma patients, we cloned the T cells in PBLs using limiting dilution conditions in which 100% of OKT4+ and OKT8+ T cells in normal PBLs are able to form a clone. In contrast, the OKT8+ cells from PBLs of five of seven multiple myeloma patients were severely compromised in their clonogenic potential; only 7% to 25% of OKT8+ T cells appeared to give rise to a clone. Clonogenic potential of the OKT4+ cells in patients was more nearly normal. Analysis of two multiple myeloma patients with abnormally low numbers of T cells in PBLs revealed the existence of abnormalities in the progenitors of T cell clones. In both patients, two to three times as many T cell clones were observed as would have been expected based on the number of PBLs cultured at limiting dilution, indicating that OKT4-8- cells in PBLs are capable of giving rise to OKT4+ and, at lower frequency, to OKT8+ clonal progeny in vitro. We conclude that purely quantitative assessment of T cell subsets should be interpreted with caution, since proportionately normal numbers of OKT8+ cells in patient PBLs are seriously compromised in their ability to give rise to clonal progeny in vitro, and since there appears to be a OKT4-8- population of T cells in PBLs that are committed to become OKT4+ or OKT8+ T cells, but are unable to do so in vivo.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3904868

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  5 in total

Review 1.  Mechanisms of polyclonal hypogammaglobulinaemia in multiple myeloma (MM).

Authors:  M C Kyrtsonis; A Mouzaki; A Maniatis
Journal:  Med Oncol       Date:  1999-07       Impact factor: 3.064

2.  Humoral immune deficiency in multiple myeloma patients due to compromised B-cell function.

Authors:  L M Pilarski; E J Andrews; M J Mant; B A Ruether
Journal:  J Clin Immunol       Date:  1986-11       Impact factor: 8.317

3.  A disturbance of the IL-2/IL-2 receptor system parallels the activity of multiple myeloma.

Authors:  A Vacca; R Di Stefano; A Frassanito; G Iodice; F Dammacco
Journal:  Clin Exp Immunol       Date:  1991-06       Impact factor: 4.330

4.  Selective loss of CD4+ CD45R+ T cells in peripheral blood of multiple myeloma patients.

Authors:  H M Serra; M J Mant; B A Ruether; J A Ledbetter; L M Pilarski
Journal:  J Clin Immunol       Date:  1988-07       Impact factor: 8.317

5.  Late immune and haemopoietic functions in plasmacytoma-bearing mice cured by melphalan.

Authors:  O Sagi; I P Witz; B Ramot; E Sahar; D Douer
Journal:  Br J Cancer       Date:  1988-03       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.